IMV News and Press, IMV Inc.

GAAP Net Income of $8.3 million or $0.25 per diluted share Non-GAAP Net Income of $11.0 million or $0.33 per diluted share Declares Third Consecutive Quarterly Dividend Immersion Corporation (NASDAQ: IMMR), a leading developer and provider of technologies for haptics, to...

2023-05-08 18:08:38 ET IMV ( NASDAQ: IMV ) said Monday it was notified by Nasdaq that its stock will be delisted as a result of the Nova Scotia Supreme Court granting the firm protection under CCAA . Trading of the company's shares would be suspended at the openin...

IMV Inc. (the “ Company ” or “ IMV ”) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX ® platform to treat solid and hematologic cancers, today announced tha...

Horizon Technology Finance Announces First Quarter 2023 Financial Results PR Newswire - First Quarter 2023 Net Investment Income per Share of $0.46 ; NAV per Share of $11.34 - - Debt Portfolio Yield of 16.3% - - Grew Portfolio Year over Year by 39% to ...

2023-05-02 11:50:41 ET H.C. Wainwright downgraded immuno-oncology company IMV Inc. ( NASDAQ: IMV ) to Neutral from Buy on Tuesday, citing the need for more clarity over the strategic review the Canada-based biotech has undertaken. The downgrade comes close on the heels of IMV&#x...

IMV Inc. (the “ Company ” or “ IMV ”) (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical Company developing a portfolio of immune-educating therapies based on its novel DPX ® platform to treat solid and hematologic cancers, announced today tha...

Immersion To Report Q1 2023 Financial Results Immersion Corporation (NASDAQ: IMMR), a leading developer and provider of technologies for haptics, today announced that it has signed a multi-year license to Immersion’s technology with Motrex Co., Ltd., a manufacturer and developer ...

IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies, based on its novel DPX platform, to treat solid and hematologic cancers, today announced changes to its board of directors as Shermaine Tilley, Ph.D., MBA has resigned from the Board o...

2023-03-16 11:02:16 ET The following slide deck was published by IMV Inc. in conjunction with their 2022 Q4 earnings call. For further details see: IMV Inc. 2022 Q4 - Results - Earnings Call Presentation

2023-03-16 11:02:08 ET IMV Inc. (IMV) Q4 2022 Earnings Conference Call March 16, 2023 08:00 ET Company Participants Andrew Hall - Chief Executive Officer Brittany Davison - Chief Accounting Officer Jeremy Graff - Chief Scientific Officer Conference Call Par...